Sotio Biotech Ag
Clinical trials sponsored by Sotio Biotech Ag, explained in plain language.
-
Promising cancer combo trial halted early
Disease control TerminatedThis study tested a new drug called SOT101 (nanrilkefusp alfa) combined with pembrolizumab in 166 people with advanced solid tumors like lung, colon, and ovarian cancer. The goal was to see if the combo could shrink tumors. The trial was stopped early, so results are limited.
Phase: PHASE2 • Sponsor: SOTIO Biotech AG • Aim: Disease control
Last updated Jun 18, 2026 11:49 UTC
-
New drug combo tested for tough cancers
Disease control TerminatedThis early-stage study tested a new drug called SO-C101, either alone or with another drug (pembrolizumab), in 115 people with advanced solid tumors like lung, kidney, or skin cancer. The main goal was to see if the treatment was safe and to look for early signs of tumor shrinkag…
Phase: PHASE1 • Sponsor: SOTIO Biotech AG • Aim: Disease control
Last updated Jun 16, 2026 12:48 UTC